Wegovy and Ozempic are made by the same company (Novo Nordisk) and contain the same active ingredient (semaglutide). The difference comes down to dose and FDA-approved indication: Wegovy 2.4 mg weekly is approved for chronic weight management and cardiovascular risk reduction; Ozempic up to 2 mg weekly is approved for type 2 diabetes. For weight loss, Wegovy produces about 15 percent body weight reduction versus 5 to 7 percent for Ozempic at its diabetes doses. Which one is “better” depends entirely on your indication and what your insurance covers.
Side-by-Side Comparison
| Feature | Wegovy | Ozempic |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| Manufacturer | Novo Nordisk | Novo Nordisk |
| FDA-approved use | Chronic weight management; CV risk reduction in obesity | Type 2 diabetes; CV risk reduction in T2D + CVD |
| Maximum dose | 2.4 mg weekly | 2 mg weekly |
| Starting dose | 0.25 mg weekly | 0.25 mg weekly |
| Titration | Monthly to 0.5, 1, 1.7, 2.4 mg | Monthly to 0.5, 1, 2 mg |
| Average weight loss | ~15% (STEP trials) | ~5–7% (SUSTAIN trials) |
| Average A1C reduction | Not labeled — diabetes not primary indication | 1.5–2.0 percentage points |
| Cardiovascular outcomes trial | SELECT (20% MACE reduction) | SUSTAIN-6 (26% MACE reduction) |
| Pen color | Color-coded by dose | Color-coded by dose |
| Frequency | Weekly subcutaneous injection | Weekly subcutaneous injection |
| Typical list price | ~$1,350/month | ~$970/month |
| Common insurance coverage | Often excluded under weight-loss carveouts | Often covered for T2D |
What Each One Is
Wegovy is semaglutide formulated at higher doses for chronic weight management. It is approved for adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity. In 2024 it gained an additional indication for reducing the risk of major adverse cardiovascular events in adults with overweight/obesity and established cardiovascular disease.
Ozempic is semaglutide at doses up to 2 mg weekly, approved for glycemic control in adults with type 2 diabetes. It also has a cardiovascular risk reduction indication for adults with type 2 diabetes and established cardiovascular disease, based on the SUSTAIN-6 trial.
Efficacy Differences
| Outcome | Wegovy 2.4 mg | Ozempic 1 mg | Ozempic 2 mg |
|---|---|---|---|
| Weight loss (68 wk) | ~14.9% | ~4.5–6% | ~6.9–7.5% |
| A1C reduction | Not labeled | ~1.4–1.6% | ~1.8–2.1% |
| Cardiovascular MACE reduction | ~20% (SELECT) | ~26% (SUSTAIN-6) | — |
| Patients achieving ≥ 10% weight loss | ~69% | ~30% | ~38% |
Dosing Schedules
Both medications use the same titration philosophy — start low and step up monthly to minimize gastrointestinal side effects.
- Wegovy: 0.25 mg weeks 1–4 → 0.5 mg weeks 5–8 → 1.0 mg weeks 9–12 → 1.7 mg weeks 13–16 → 2.4 mg weeks 17+
- Ozempic: 0.25 mg weeks 1–4 → 0.5 mg weeks 5+ → (if needed) 1 mg after 4 more weeks → 2 mg after 4 more weeks
Slowing titration is acceptable for both if side effects are intolerable.
When to Choose One Over the Other
Wegovy may be the better choice when:
- The primary goal is weight loss
- BMI meets obesity criteria and insurance covers obesity therapy
- You have established cardiovascular disease without type 2 diabetes
- Type 2 diabetes is not present
Ozempic may be the better choice when:
- You have type 2 diabetes — this is the labeled indication
- Insurance covers Ozempic but not Wegovy
- Glycemic control is the primary goal
- You have type 2 diabetes plus cardiovascular disease
Side Effects (Both)
- Nausea, vomiting, diarrhea, constipation — usually worst in first 4 to 8 weeks
- Decreased appetite
- Heartburn or reflux
- Fatigue in early weeks
- Injection site reactions
- Gallbladder issues (cholelithiasis, cholecystitis)
- Pancreatitis (rare)
- Boxed warning for thyroid C-cell tumors — contraindicated with personal or family history of medullary thyroid carcinoma or MEN 2
- Acute kidney injury (often dehydration-driven)
Higher Wegovy doses tend to produce slightly more frequent and prolonged GI symptoms, though both medications taper symptoms with slow titration.
Cost and Coverage
List prices are roughly $1,350/month for Wegovy and $970/month for Ozempic. Both have manufacturer savings cards that can reduce commercial copays substantially. Coverage diverges sharply:
- Wegovy — frequently excluded by U.S. commercial plans under weight-loss carveouts; Medicare Part D historically excluded it but the 2024 cardiovascular indication is opening coverage for some patients
- Ozempic — generally covered for type 2 diabetes under commercial and Medicare plans, usually with prior authorization
Switching Between Them
Because both contain semaglutide, switching is typically straightforward. The prescriber matches your current dose to the closest dose of the other product and continues titration. Insurance prior authorization is the larger hurdle, not the medical transition. Read more about treatment pathways.
Off-Label Considerations
Some clinicians prescribe Ozempic off-label for weight management when Wegovy is not covered. This produces lower weight loss than Wegovy at the labeled 2.4 mg dose, but at the 2 mg Ozempic dose it can deliver around 7 to 9 percent weight loss. Off-label use does not change FDA approval status and may complicate insurance approval. Talk to your doctor about whether this approach is appropriate.
Lifestyle Pairing
Both medications work best alongside reduced-calorie diet and increased physical activity. Read more about diet for sustained weight loss and A1C targets.
The Bottom Line
Wegovy and Ozempic are the same molecule (semaglutide) at different doses for different indications. Wegovy at 2.4 mg weekly is approved for obesity and cardiovascular risk reduction in obesity, producing roughly 15 percent weight loss. Ozempic up to 2 mg weekly is approved for type 2 diabetes, producing 5 to 7 percent weight loss and 1.5 to 2 percentage points of A1C reduction. Side effects are nearly identical. The choice between them depends primarily on your indication and what your insurance covers. Talk to your doctor about which is the right fit, and check your formulary before assuming coverage.
